The CSL Limited (ASX: CSL) share price has been out of form in recent weeks.
So much so, the biotherapeutics giant’s shares are down almost 8% since this time last month at $278.75.
This means the CSL’s shares are now in negative territory year to date with a 2% decline.
Why is the CSL share price down 8% in a month?
Investors have been selling down the CSL share price over the last few weeks following the release of a couple of reasonably bearish broker notes.
One of those came from investment bank Citi towards the end of June. According to the note, the broker has downgraded the company’s shares to a neutral rating with a $310.00 price target.
Its analysts made the move on valuation grounds, believing that its recovery was priced in on 23 June when the CSL share price was fetching ~$300.
Citi commented: “We move CSL to Neutral (from Buy) given the outperformance of the stock since March. We remain 15% ahead of consensus for FY23E, and believe that the plasma collection market will normalize this year. Our rating change is purely valuation based. Risk to the upside remains if the CSL112 phase III trial result due at the end of CY21 is positive.”
What else happened?
Also weighing on the CSL share price was a similarly mixed note out of Credit Suisse released two days later. According to that note, the broker downgraded CSL’s shares to a neutral rating and cut the price target on them to $310.00.
Credit Suisse warned that a short term de-rating of the company’s shares could happen due to potential margin weakness in the near term caused by plasma collection headwinds. The broker is forecasting a gross margin of 54.1% for its CSL Behring business in FY 2022, down from 61.2% in FY 2020.
CSL is likely to provide guidance next month with its full year results release. All eyes will be on those margins.